# A Comparison of the dermaPACE® (Pulsed Acoustic Cellular Expression) Device in Conjunction With Standard of Care Versus Standard of Care Alone in the Treatment of Diabetic Foot Ulcers

> **NCT01824407** · PHASE3 · UNKNOWN · sponsor: **SANUWAVE, Inc.** · enrollment: 90 (estimated)

## Conditions studied

- Diabetic Foot Ulcers

## Interventions

- **DEVICE:** Electrohydraulic-generated shock wave
- **DEVICE:** Sham device plus standard of care

## Key facts

- **NCT ID:** NCT01824407
- **Lead sponsor:** SANUWAVE, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-03
- **Primary completion:** 2014-04
- **Final completion:** —
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2014-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01824407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01824407, "A Comparison of the dermaPACE® (Pulsed Acoustic Cellular Expression) Device in Conjunction With Standard of Care Versus Standard of Care Alone in the Treatment of Diabetic Foot Ulcers". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01824407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*